A method for the simultaneous measurement of the new anthracycline derivative 4′ -deoxydoxorubicin and its metabolites by reversed phase liquid chromatography

Yei Mei Peng, David S. Alberts, Sydney E. Salmon, Thomas P. Davis

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

The anthracycline analog 4′-deoxydoxorubicin (4′ -deoxyDX) is a clinically promising antineoplastic agent due to its high potency, broad spectrum of activity, and decreased cardiotoxicity relative to DX. To assess its physicochemical properties and disposition kinetics, we have developed a rapid, sensitive, and precise HPLC assay for the simultaneous analysis of 4′ -deoxyDX and its potential metabolites in biological samples. The assay has a detection limit of 5 ng/ml with an average recovery of 95 ± 5%. Precision of the assay is less than 7%. Using this assay we have measured the concentrations of 4′-deoxyDX in patient plasma and urine after an intravenous injection of 4′-deoxyDX. A major metabolite, which co-eluted chromatographically with 4′-deoxydoxorubicinol, was observed in both plasma and urine.

Original languageEnglish (US)
Pages (from-to)277-280
Number of pages4
JournalInvestigational New Drugs
Volume2
Issue number3
DOIs
StatePublished - Sep 1 1984

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A method for the simultaneous measurement of the new anthracycline derivative 4′ -deoxydoxorubicin and its metabolites by reversed phase liquid chromatography'. Together they form a unique fingerprint.

  • Cite this